Humanigen (HGENQ) Akcie Kurz
Humanigen Kurz
Tržby rostly o 11,8 % ročně za posledních 13 let na 2,51 Mil. USD. čistá marže společnosti Humanigen je nyní -2 817,9 %, dolů z -385,4 % před několika lety.
Cena akcie Humanigen
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model Humanigen a analýza akcií
Nejčastější otázky týkající se akcie Humanigen
The main competitors of Humanigen Inc in the market include pharmaceutical companies such as Eli Lilly and Company, Gilead Sciences Inc, and Regeneron Pharmaceuticals Inc.
Humanigen Inc is a biopharmaceutical company with a focus on advancing transformative monoclonal antibody therapeutics. Their business model revolves around developing and commercializing cutting-edge treatments to address unmet medical needs. Humanigen Inc utilizes its proprietary Humaneered® technology platform to create novel antibodies that target and neutralize disease-causing mechanisms in various diseases such as cancer and infectious diseases. Through strategic partnerships and collaborations, Humanigen Inc aims to bring innovative therapies to patients and improve their quality of life.
Humanigen Inc is primarily active in the biotechnology industry.
Humanigen Inc is a biopharmaceutical company specializing in developing and commercializing cutting-edge immunotherapies for various challenging diseases. Founded in 1997, Humanigen has a rich history in researching innovative treatments, including its proprietary Humaneered® antibody technology platform. With a focus on providing life-changing therapies, Humanigen strives to improve patient outcomes and enhance the quality of life for individuals worldwide. The company's dedication to advancing science and delivering effective solutions has positioned Humanigen as a leader in the biopharmaceutical industry.
Humanigen Inc has achieved several significant milestones. One notable accomplishment is the development of their lead product candidate, lenzilumab. This innovative monoclonal antibody has shown promise in treating various diseases, including COVID-19 and CAR-T therapy-related side effects. Humanigen Inc has also made progress in advancing clinical trials for lenzilumab, with positive results demonstrating its potential efficacy. Furthermore, the company has secured partnerships and collaborations to further enhance their research and development efforts. These milestones highlight Humanigen Inc's commitment to driving advancements in healthcare and their dedication to improving patient outcomes.
Humanigen Inc is primarily present in the United States.
Humanigen Inc represents values of innovation, dedication, and patient-centered care. As a biopharmaceutical company, Humanigen is committed to developing cutting-edge therapies to address unmet medical needs. With a focus on precision medicine and next-generation solutions, the company aims to improve the lives of patients worldwide. Humanigen Inc's corporate philosophy is centered around scientific excellence, ethical conduct, and a mission-driven approach to transform healthcare. By leveraging its expertise and collaborative partnerships, Humanigen strives to offer effective and accessible treatments to patients while ensuring the highest standards of quality and safety.
8 analytiků aktuálně hodnotí akcii Humanigen: 0 doporučuje koupit, 3 držet a 5 prodat.
Akcie Humanigen (HGENQ) je kótována na 4 burzách, mimo jiné: NASDAQ (HGEN), Frankfurt (0KB2.F), München (0KB2.MU), Düsseldorf (0KB2.DU).
The company Humanigen Inc. is a biopharmaceutical company specializing in the development and marketing of treatments for rare and serious diseases. Its business model includes various sectors, including research and development, manufacturing and marketing of drugs, as well as research in collaboration with academic and nonprofit institutions.
Tržby nelze pro Humanigen aktuálně vypočítat.
Zisk nelze pro Humanigen aktuálně vypočítat.
Poměr P/E nelze pro Humanigen aktuálně vypočítat.
Poměr P/S nelze pro Humanigen aktuálně vypočítat.
Score kvality pro Humanigen je 3/10.
ISIN Humanigen je US4448632038. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN Humanigen je A2QEQW. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker Humanigen je HGENQ. Symbol tickeru se používá k obchodování akcií Humanigen na burze.
Humanigen akcie
Humanigen Peer Group
Humanigen Ticker
Humanigen FIGI
Všechny fundamentální údaje o Humanigen v podrobné analýze
Naše analýzy akcií společnosti Humanigen zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Humanigen. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: